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Abstract
Background: The concept of dependence has been proposed as a unified representation of disease severity to
quantify and stage disease progression in a manner more informative to patients, caregivers, and healthcare
providers.
Methods: This paper provides a review of the Dependence Scale (DS) as a quantitative measure of Alzheimer’s
disease severity, its properties as an outcome measure, a metric of disease progression, and a correlate of medical
costs.
Results: The literature supports the notion that the DS is related to, but distinct from, key severity measures,
including cognition, function, and behavior, and captures the full spectrum of patient needs. It also presents as a
useful measure for assessing disease progression.
Conclusions: Results underscore the importance of the DS as a unique endpoint in Alzheimer’s disease clinical
trials, providing important information about the impact of therapeutic interventions. The DS also is a useful
measure for economic evaluation of novel interventions aimed at delaying progression.
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Background
The severity of Alzheimer’s disease (AD) and its progres-
sion over time are generally captured on scales that
measure distinct domains of cognition, function, and be-
havior. Several issues arise with this approach. While of-
fering clinicians a valuable tool for quantifying mental
functions, these scales are often of limited meaningful-
ness to patients and caregivers, who may be better
served with a broad, relatable representation of individu-
alized disease impact. Focusing treatment on one aspect
of the disease (e.g., behavior) could result in other as-
pects being insufficiently addressed, or even adversely
impacted [1]. It can be difficult to identify clear mile-
stones that signal clinically relevant disease advancement
during AD patients’ gradual decline in ways that are
meaningful to patients and caregivers [2].
As a result of these shortcomings, the concept of de-
pendence has been proposed as a unified representation
of disease severity to quantify and stage disease progres-
sion in a manner more informative to patients, their
healthcare providers, and caregivers [3]. Progressive cog-
nitive impairment and behavioral disturbances in AD
lead to increasing loss of function and independence.
Dependence is thus considered to be related to the de-
gree of impairment in multiple domains, but is distinct
and complementary to each.
A number of scales have been developed to measure
dependence, of which the Dependence Scale (DS) has
been most widely studied [3]. Other instruments devel-
oped to measure dependence include the Record of In-
dependent Living (RIL) [4], Independent Living Scales
(ILS) [5], the Behavioral Rating Scale for Geriatric Pa-
tients (BGP) [6], and the Nursing Care Dependency
(NCD) scale [7]. The merits of these scales have been
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discussed elsewhere [1]. Here, we review the DS as a
quantitative measure of disease severity in AD and re-
view its properties as a study outcome measure, a metric
of disease progression, and a correlate of medical costs,
and thereby its meaningfulness to patients, their care-
givers, and other stakeholders.
Search approach
An initial MEDLINE search of all indexed journals pub-
lished in English was conducted by using dependence,
dependency, or dependence scale in the abstract or title
or as MeSH terms and with dementia or Alzheimer in
the abstract or title, yielding 117 potentially relevant
articles for which full text is available online. A
semi-structured review of abstracts was then conducted
and excluded 45 articles that included search terms that
were unrelated to the current study, e.g., article focusing
on alcohol, drug, substance, or environmental depend-
ency, studies in basic science, brain/spinal injury, or con-
ditions other than dementia. We also excluded 23
articles that used activities of daily living (ADLs) exclu-
sively to define dependence, four that focused on Zarit
Burden Index, and seven that were published more than
20 years ago (before 1998). Of the 38 remaining articles
that described some measure of dependence in dementia
or AD, 15 described other measures of dependence and
were excluded. Reference lists from the remaining 23 ar-
ticles that focused on the Dependence Scale were
reviewed for potential additional relevant articles.
The Dependence Scale
The DS is composed of 13 items, which include 11 di-
chotomous (yes/no) items and two items scored on a
three-point scale, indicating frequency of need (never/
occasionally/frequently) (Table 1). The total DS score is
the sum of all 13 items, which ranges from 0 to 15,
where higher scores indicate more dependence (i.e., loss
of independence). The 13 items on the DS were based
on items found to reflect functional deficiencies import-
ant to patients with AD [8]. Individual items on the scale
capture patients’ need for reminders and cueing in daily
activities and practical activities, as well as the degree to
which patients need supervision when awake. As such,
several of the assessed needs are not linked to the per-
formance of specific tasks. The items are hierarchical,
each item representing the need for increasing levels of
assistance. A patient that is dependent on a more severe
item should also be dependent on the less severe items
on the DS [3]. It should be noted that the DS measures
the amount of assistance needed by the AD patient; it
does not necessarily indicate how much assistance he or
she receives. There may be factors extraneous to AD,
such as lack of caregivers, nursing home beds or insur-
ance coverage, socioeconomic and sociocultural factors,
as well as country-specific healthcare policies that influ-
ence actual amount of care received. The DS can be
administered to an individual close to the patient, who is
familiar with the patient’s care requirements by an inter-
viewer with minimal training. After scoring the 13 items
on the DS, the items can be used to derive a dependence
level, ranging from 0 (no dependence) to 5 (complete
dependence) (Table 2).
Psychometric properties of the Dependence Scale
The initial validation for the DS was performed in the
Predictors study cohort of patients with mild to moder-
ate AD, in which the DS demonstrated consistency with
Table 1 The Dependence Scale
Score
A Does the patient need reminders or advice to manage
chores, do shopping, cooking, play games, or handle
money?
0/1/2
B Does the patient need help to remember important
things such as appointments, recent events, or names
of family or friends?
0/1/2
C Does the patient need frequent (at least once a month)
help finding misplaced objects, keeping appointments,
or maintaining health or safety (locking doors, taking
medication)?
0/1
D Does the patient need household chores done for them? 0/1
E Does the patient need to be watched or kept company
when awake?
0/1
F Does the patient need to be escorted when outside? 0/1
G Does the patient need to be accompanied when
bathing or eating?
0/1
H Does the patient have to be dressed, washed, and
groomed?
0/1
I Does the patient have to be taken to the toilet
regularly to avoid incontinence?
0/1
J Does the patient have to be fed? 0/1
K Does the patient need to be turned, moved, or
transferred?
0/1
L Does the patient wear a diaper or a catheter? 0/1
M Does the patient need to be tube fed? 0/1
Dependence Scale Total Score /15
Coding for items A/B: No (0), Occasionally (at least once a month) (1) ,
Frequently (at least once a week) (2)
Coding for items C–M: no (0), yes (1)
Table 2 Derivation of dependence level
Level 0 0 to all items
Level 1 Either A, B, or C = 1
Level 2 2 of A, B, or C = 1 OR A or B = 2 OR D = 1
Level 3 E, F, or G = 1
Level 4 H, I, or J = 1
Level 5 K, L, or M = 1
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scales to assess cognitive and functional impairment as
well as strong inter-rater reliability (intraclass correlation
of 0.90) and acceptable internal consistency (Cronbach’s
α of 0.66) [3]. These robust psychometric properties
have since been reproduced in several independent stud-
ies (Table 3). Content validity of the DS was confirmed
in qualitative assessments amongst clinicians, caregivers,
and patients in multiple North American and European
countries, substantiating the importance of the items on
the DS to AD patients and their caregivers [9]. Analyses
using cohorts of subjects with mild to moderately severe
AD (MMSE > 10) from the Predictors studies, the DADE
study, and the ELN-AIP-901 separately confirmed the
DS’s internal consistency index of > 0.70 [3, 10, 11],
which exceeds established threshold for reliability [12].
Additionally, an investigation of validity, reliability, and
responsiveness of the DS in a large randomized
placebo-controlled clinical trial demonstrated utility of
the DS in this setting [13]. In assessing responsiveness
(i.e., ability to detect change in patients receiving an
intervention), change in total DS score between baseline
and trial completion was found to be significantly corre-
lated to change scores in other outcomes [13]. A study
assessing criterion validity of the DS, comparing total
DS score to another dependence-related measure (Offi-
cial Scale for the Assessment of Dependence and Dis-
ability of the Spanish Ministry of Health, Social Policy
and Equality (OSADD)) found the two dependence mea-
sures strongly correlated (r = 0.885; p < 0.001) [14].
The Dependence Scale and other clinical measures of
Alzheimer’s disease severity
Cognition, function, and behavior
Various studies have examined correlation between the
DS and frequently used clinical measures of AD severity.
Stern et al. [3] found that the dependence level at base-
line significantly but weakly correlated with modified
Mini Mental State Exam (mMMS; r = − 0.27), Clinical
Dementia Rating (CDR) score (r = 0.34), and the cogni-
tive (r = 0.38) and basic self-care factors (r = 0.26) of the
Blessed Dementia Rating Scale (BDRS; p < 0.001). The
cross-sectional DADE study in the UK showed a signifi-
cant association between total DS score and cognition
(MMSE; r = − 0.47), global disease severity (Clinical De-
mentia Rating Scale Sum of Boxes (CDR-SB); r = 0.64),
function (Disability Assessment for Dementia (DAD); r
= − 0.72), and a weaker association with behavior
(Neuropsychiatric Inventory (NPI); r = 0.21) [11]. More-
over, this study showed that DAD, MMSE, and CDR-SB
could explain 68%, 44%, and 59% of variation in total DS
score, respectively (p < 0.01). In the combined Predictors
studies at baseline, total DS score correlated strongest
with BDRS (r = 0.60), while the Columbia University
Scale of Psychopathology in Alzheimer’s disease (CUS-
PAD; r = 0.25) and mMMS (r = − 0.30) showed weaker
correlations (all p < 0.0001) [10]. The ELN-AIP-901
study showed a similar correlation between total DS
score and other measures at 26 and 78 weeks. The
strongest correlation was with the DAD score (r = − 0.77
Table 3 Validation studies assessing the psychometric properties of the DS
Study Population n Outcome
Stern et al. 1994 [3]: Predictors
I study
Mild–moderate AD 249 Inter-rater reliability (interclass correlation), 0.99 for total score; internal
consistency (Cronbach’s α), 0.66; significant correlation with CDR
(r = 0.34) and mMMS (r = − 0.27)
Lenderking et al. 2013 [10]: Predictors
I + II studies
Mild-moderate AD 460 Internal consistency (Cronbach’s α), 0.72; construct validity, correlation
with BDRS (r = 0.60), mMMS (r = − 0.30)
Lenderking et al. 2013 [10]; DADE
Study
Mild-moderate AD 172 Internal consistency (Cronbach’s α), 0.72; construct validity, significant
correlation with MMSE (r = − 0.47), CDR-SB (r = − 0.64), DAD (r = − 0.72),
and NPI (r = 0.21)
Lenderking et al. 2013 [10]: ELN-AIP
901 study
Mild-moderate AD 166 Internal consistency (Cronbach’s α), 0.74; construct validity, significant
correlation with MMSE (r = − 0.53), ADAS-cog (r = − 0.42), DAD
(r = − 0.77), and NPI (r = 0.51)
Wyrwich et al. 2014 [13] Mild-moderate AD 2334 Internal consistency (Cronbach’s α), 0.66; construct validity, significant
correlation with ADAS-cog (r = 0.36), MMSE (r = − 0.34), DAD (r = − 0.63),
CDR-SB (r = 0.61), and NPI (r = 0.32); responsiveness, significant correlation
with change scores on ADAS-cog, DAD, CDR-SB, and MMSE (baseline
to week 78)
Brickman et al. 2002 [18]: Predictors
1 study
Mild-moderate AD 230 Statistically significant change in total DS score over time (0.5 points per
6 month interval) (p < 0.001).
Garre-Olmo et al. 2015 [14]: CoDep
AD study*
Mild-severe AD 343 Internal consistency (Cronbach’s α), 0.85; significant correlation with DAD
score (r = 0.900), CBI (r = 0.323), NPI (r = 0.374), and MMSE (r = 0.617)
CDR clinical dementia rating, MMSE Mini Mental State Examination, mMMS modified MMSE, BDRS blessed dementia rating scale, CDR-SB Clinical Dementia Rating
Scale Sum of Boxes, DAD disability assessment for dementia, ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale, NPI neuropsychiatric inventory,
CBI caregiver burden interview. *Spanish translation of DS
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and r = − 0.74 at 26 and 78 weeks, respectively), followed
by MMSE (r = − 0.53 and r = − 0.55 at 26 and 78 weeks,
respectively) [10]. Similarly, after converting functional
scores (ADCS-ADL) in a European cohort (GERAS
study, n = 1497 AD patients) to dependence levels, it
was found that higher levels of dependence correlated
with decreased MMSE and NPI scores (p < 0.001) [15,
16]. The DS also was validated in a cohort of 343 Span-
ish participants, with a strong correlation between total
DS score and DAD (r = − 0.90). It was also found that
the relative contributions of cognitive, functional, and
behavioral measures to total DS score change at various
stages of the disease, supporting the unifying quality of
dependence as a construct [14]. Similar to findings from
the DADE study, DAD was the strongest predictor of
total DS score variability (50.3% in mild AD and 64.2%
in severe AD) in the Spanish-language version of the DS
[14]. Similarly, a study using the Austrian PRODEM
cohort of mild to moderate AD patients found the
strongest correlation between total DS score and DAD
(r = 0.79) followed by CDR (r = 0.54), NPI (r = 0.35), and
MMSE (r = − 0.31) (all p < 0.001) [17].
Assessing the DS over time in a randomized placebo-
controlled clinical trial setting, change in total DS score
correlated to change scores in Alzheimer’s Disease Assess-
ment Scale-cognitive subscale (ADAS-cog; r = 0.40),
CDR-SB (r = 0.48), DAD (r = − 0.51), MMSE (r = − 0.45),
and NPI (r = 0.41) [13].
Multiple studies have demonstrated the construct val-
idity of the DS, showing significant increase in depend-
ence over time, independent of global cognition and
other self-care deficits, demonstrating the sensitivity of
the DS to natural progression of AD [18, 19]. In the Pre-
dictors 1 study, an increase of 0.5 points per 6 months
in the total DS score was observed [20]. Dependence
levels increased by 0.26 after 6 months and 0.45 after
1 year [3]. In the combined Predictors 1 and Predictors
2 cohort a similar increase of 1.03 points in the total DS
score per year was reported [21]. In another study of
non-institutionalized AD patients, a worsening of 1.2
points was observed after 12 months of follow-up [22].
In the Predictors 1 study, a one-point change in the
total DS score over 18 months was correlated with sta-
bility in living situation, i.e., remaining in own home or
remaining in assisted living [10]. Patients that progressed
in living situation, requiring higher levels of care (e.g.,
progressing from own home to assisted living) showed a
larger increase in the total DS score, ranging from 2.31
to 5.81 points higher than those with a stable living situ-
ation. This was confirmed in a mild AD population
(MMSE ≥ 21), in which an approximately one-point
change in the total DS score was seen with stable living
situation after 78 weeks; however, in the moderate AD
(MMSE ≤ 20) subgroup of patients that remained at a
stable living situation, an increase of 1.5–2 points in the
DS score was observed.
Dependence Scale and health economic outcomes
As the prevalence of the disease increases and cost of
care continues to stress healthcare systems, cost consid-
erations of current and novel therapies in AD are of high
importance. Generally, cost of care of AD patients in-
creases with greater disease severity. This holds true for
severity captured by cognitive, functional, and behavioral
measures [23].
A systematic review of methods of cost estimation in
AD concluded that there was no established consensus on
the appropriate method to model progression of AD for
use in cost analyses [24]. A review of studies that exam-
ined the association between cognitive, functional, and be-
havioral endpoints and costs associated with AD found
that cognition, function, and behavioral dysfunction each
were independently associated with cost but any one of
these measures alone did not fully represent healthcare
cost [23]. Consequently, it is proposed that measures of
cognition, function, and behavior be included in cost ana-
lyses simultaneously or, alternatively, a composite measure
be used that captures deficiencies in each measure. De-
pendence on others as measured by the DS has been sug-
gested as a unifying construct better suited than individual
measures of cognition, function, and behavior to estimate
the economic impact of AD [1, 19].
In the ELN-AIP-901 study cohort, the MMSE, DAD,
and CDR were compared side-by-side to the DS to as-
sess their utility in economic modeling [25]. Total DS
score demonstrated the highest correlation to direct cost
(R2 = 0.22, p = 0.004), followed by DAD (R2 = − 0.021, p
= 0.006), while MMSE and CDR were not significantly
correlated with cost. In addition, the DS and DAD had
the highest correlation with caregiver time (R2 = − 0.52,
p < 0.0001 and R2 = 0.49, p < 0.0001, respectively).
In several studies by Zhu et al. the association between
dependence and cost was longitudinally examined in the
Predictors study cohort [19, 26–28]. The DS was signifi-
cantly associated with total cost. A one-point increase in
the total DS score was associated with a US$1832 increase
in total annual costs. The DS was found to have the stron-
gest association with informal costs (caregiver time in as-
sistance with activities of daily living (ADL)) [26]. In a
separate study, dependence was significantly associated
with medical costs (5.7% increase in cost per one DS point)
and caregiver time (4.1% increase per one DS point) inde-
pendent of functional impairment [24].
In cross-sectional analyses in European cohorts, the
association between DS and cost was shown to be inde-
pendent of function or other severity measures [29–31].
A one-point increase in the total DS score was corre-
lated with a €796 increase in total cost in an Irish cohort
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of non-institutionalized patients with AD or MCI. In the
same cohort followed for 2 years it was found that a
one-point increase in the total DS score increased costs by
19%, mostly attributable to increases in informal care costs
through caregiver time [29]. In the DADE study, a one-point
increase in the total DS score was associated with £321 in-
crease in cost of care, excluding unpaid care costs [11].
The Co-Dependence in Alzheimer’s Disease study in
Spain assessed the association with multiple cost variables
from dependence, time since diagnosis, comorbidities, and
living situation. The DS was found to be the only mea-
sured variable independently associated with medical care
cost, social care cost, indirect cost, and informal care cost
[32]. A one-point increase in the total DS score was asso-
ciated with a 13.5% increase in direct medical care costs, a
25.3% increase in social care costs, and a 214.7% increase
in informal care costs of 6 months.
Using data from the Predictors 1 study, it was demon-
strated that the DS was useful in prospectively predicting
home health aide (HHA) use [33]. The annual probabil-
ity of transitioning to needing a HHA increased as the
total DS score increased, from 4% at a DS score of 1 to
54% at a DS score of 10. Specifically, three items of the
DS (needing household chores done for oneself, needing
to be watched or kept company when awake, and need-
ing to be escorted when outside) were found to be sig-
nificant predictors of the presence of an HHA.
Patient quality of life
The ability of an AD severity measure to bridge AD
symptomatology and quality of life (QoL) outcomes is of
particular importance when determining its utility in
assessing disease progression and guiding policy [25]. In
the ELN-AIP-901, total DS score showed the highest
correlation with Quality of Life-Alzheimer’s Disease
(QoL-AD; r = − 0.52, p < 0.0001) compared to MMSE,
DAD, and CDR scores (r = 0.25, r = 0.48, and r = 0.39, re-
spectively; all p < 0.0001). Total DS score explained the
greatest variance in QoL (R2 = 0.33) compared to DAD,
CDR, and MMSE [25]. Several other cross-sectional ana-
lyses have shown decreased QoL with increasing de-
pendence [15]. In the cross-sectional DADE study, QoL
measured by both self-report and proxy scales generally
were negatively associated with the DS [11]. The longitu-
dinal change in QoL assessed in DADE-2, however, was
not associated with DS or any other measure of severity
[34]. This is potentially attributable to the large variation
in QoL in this study and a significant percentage of par-
ticipants that reported a paradoxical improvement in
QoL after 18 months.
Dependence Scale as a unifying measure
While the DS is strongly associated with other clinical
endpoints in AD, variance in the total DS score is
incompletely explained by cognitive, functional, and be-
havioral impairment alone [11, 17]. In an assessment of
the DS in the Predictors study cohort, the DADE cohort
and the ELN-AIP-901 cohort, only 50% of variance in
the total DS score was explained by cognitive, functional,
and behavioral scales [10]. Others show that functional
and behavioral measures combined with age and other
comorbidities fail to predict 26.0–40.2% of variability in
the total DS score, depending on AD severity [14]. The
Predictors study supported the distinctness of the depend-
ence construct from other AD severity measures, finding
that total DS score changes over time after correcting for
changes in cognitive and functional scores [18, 33].
Several studies used path models to examine the com-
plex relationships between key measures of AD, includ-
ing behavior, cognition, functioning, and dependence,
and examined distinctiveness of each measure and
strengths of these relationships [13, 31, 35]. Wyrwich
and colleagues examined reliability, validity, and respon-
siveness of the DS in a large randomized controlled trial
of patients with mild to moderate AD and showed that
not all of the variation in total DS score was explained
by these other key measures of AD. Two studies further
examined the relationships between different factors af-
fecting costs in dementia patients [31, 35]. In both stud-
ies, dependence, measured by the DS, was modeled as
an endogenous variable, mediating the effect of various
clinical characteristics, including cognitive, function, be-
havioral measures, and comorbid conditions. Results
showed that measures of cognition, behavior, and other
factors significantly predicted total DS score, which in
turn predicted total AD-related costs. Despite differ-
ences in the study sample and measures used, both stud-
ies showed that the significant impact that these factors
have on costs were largely mediated by dependence. To-
gether, these models support dependence as a distinct,
measurable component of dementing disease, which
ought to be an important outcome in studies of AD.
Conclusions
The DS provides a measurement of AD patients’ level of
dependence and assesses aspects of life critical to patient
autonomy. This includes the assessment of what needs
to be done for the patient, which is related to limitations
in cognition and function, but captures core aspects of
patients’ experience with AD that are distinct from and
more comprehensive than these individual measures of
disease progression.
The psychometric properties of the DS have been well
established in over two decades since its creation. The DS
has been broadly assessed in patients with AD and pro-
vides meaningful and unique information on patient needs
and independence, rather than on the ability to perform
specific tasks. By going beyond individual components of
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disease severity, the DS has specific utility in complement-
ing scales that assess cognition, function, and behavior.
Longitudinal studies have shown progression in depend-
ence over time, and the DS has also been shown to correl-
ate with numerous other scales that assess distinct
concepts of cognition, function, and behavior in AD.
While the DS and other clinical endpoints in AD are
strongly correlated, clinical scales that capture these end-
points alone incompletely drive change in the DS. Thus,
variance in the DS is poorly explained by cognitive, func-
tional, and behavioral impairment alone. In addition, the
DS has shown meaningful associations with other metrics
relevant to stakeholders in AD, including QoL metrics
and caregiver burden. The DS has also proven to be
strongly correlated to various cost aspects of AD, suggest-
ing it is a valuable unifying construct in determining value
to patients in economic assessments of interventions.
Clinical trials in AD need validated and reliable mea-
sures of disease severity that capture disease impact at
early (cognitive) and late (functional and/or behavioral)
stages, are sensitive to change over time, and are trans-
parent to all stakeholders. Most commonly used AD
scales predominantly measure severity in individual do-
mains of dysfunction. They are not sufficiently sensitive
to all AD stages, and are therefore not easily applicable
for tracking changes in routine medical practice or com-
parable in different patient populations. To date, a num-
ber of randomized controlled trials have used the DS to
characterize baseline need for care and to assess the effi-
cacy of therapeutic interventions in AD. Specifically, the
DS has been incorporated as a secondary endpoint in
AD trials exploring the efficacy of bapineuzumab [36],
selegiline [37], α-tocopherol [38], memantine [38], anti-
psychotics [39], and statins [40] in patients with varying
severities of AD.
Overall, findings presented in this review support the
notion that dependence, reflected in the psychometrically
robust DS, is related to, but distinct from, key severity
measures, including cognition, function, and behavior,
captures the full spectrum of patient needs, and is inde-
pendent of sociocultural influences. Dependence also pre-
sents as a useful measure for assessing disease progression
as it relates to cost of care, operating through unifying
multiple severity measures into a single, comprehensive
scale. This underscores the importance of the DS as a
unique endpoint in AD clinical trials, providing important
information about the impact of therapeutic interventions
on a measure of relevance to patients, caregivers, and
other stakeholders involved in the care of patients with
AD. Interventions that reduce AD patients’ dependence
are expected to contribute to reduction in costs of care.
The DS is therefore a useful measure for economic evalu-
ation of novel interventions aimed at delaying progression
to higher levels of dependence.
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